Journal
PHARMACOLOGY & THERAPEUTICS
Volume 188, Issue -, Pages 140-154Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2018.03.004
Keywords
Deacetylase; Deacylase; Inhibition; Activation; Drug discovery and development
Categories
Funding
- Deutsche Forschungsgemeinschaft [STE1701/5, STE1701/15]
- NIH [DK100263, AG028730]
Ask authors/readers for more resources
The NAD-dependent protein lysine deacylases of the Sirtuin family regulate various physiological functions, from energy metabolism to stress responses. The human Sirtuin isoforms, SIRT1-7, are considered attractive therapeutic targets for aging-related diseases, such as type 2 diabetes, inflammatory diseases and neurodegenerative disorders. We review the status of Sirtuin-targeted drug discovery and development. Potent and selective pharmacological Sirt1 activators and inhibitors are available, and initial clinical trials have been carried out. Several promising inhibitors and activators have also been described for other isoforms. Progress in understanding the mechanisms of Sirtuin modulation by such compounds provides a rational basis for further drug development. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available